大博医疗: 关于2025年度公司申请银行综合授信额度的公告

Core Points - The company plans to apply for a comprehensive credit limit of up to 1.9 billion RMB for the year 2025 to support its production, operations, and business expansion [1][2] - The credit limit will be valid from the date of approval by the shareholders' meeting until the annual shareholders' meeting in 2025 [1] Credit Limit Details - The proposed credit limits from various banks are as follows: - Agricultural Bank of China, Xiamen Branch: up to 150 million RMB - China Merchants Bank, Xiamen Branch: up to 300 million RMB - Industrial and Commercial Bank of China, Xiamen Branch: up to 150 million RMB - Xiamen International Bank, Xiamen Branch: up to 200 million RMB - Citic Bank, Xiamen Branch: up to 120 million RMB - Industrial Bank, Xiamen Branch: up to 330 million RMB - Xiamen Bank: up to 100 million RMB - China Construction Bank, Xiamen Branch: up to 250 million RMB - China Everbright Bank, Xiamen Branch: up to 100 million RMB - National Development Bank, Xiamen Branch: up to 200 million RMB [1] Financing Conditions - The credit limit does not equate to the actual financing amount, which will be determined based on the actual financing transactions between the bank and the company within the approved limit [1] - The credit limit can be used repeatedly within the authorization period, and it is granted on a full credit basis without the need for asset collateral, incurring no costs when not in use [1]